Literature DB >> 3072552

Monoclonal antibodies as magic bullets.

F M Brodsky1.   

Abstract

Monoclonal antibodies have been used as experimental therapy in humans since the beginning of the 1980s (A.N. Houghton and D. A. Scheinberg. Semin. Oncol. 13:165-179, 1986). They have been hailed as the prototypical magic bullet drug because of their inherent capacity for specificity. Consequently, monoclonal antibodies have many possible therapeutic applications with varied potential for successful outcome. Current review articles discussing monoclonal antibody therapy deal with the application of monoclonal antibodies within specific areas of medicine. The aim of this review is to summarize the current reviews and provide a broader perspective on the medical applications of monoclonal antibodies along with some general principles by which their therapeutic success or failure might be understood.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3072552     DOI: 10.1023/a:1015860525341

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  37 in total

Review 1.  In vivo diagnostic and therapeutic uses of monoclonal antibodies in cardiology.

Authors:  E Haber
Journal:  Annu Rev Med       Date:  1986       Impact factor: 13.739

2.  Antibody-directed urokinase: a specific fibrinolytic agent.

Authors:  C Bode; G R Matsueda; K Y Hui; E Haber
Journal:  Science       Date:  1985-08-23       Impact factor: 47.728

Review 3.  Structural basis of antibody function.

Authors:  D R Davies; H Metzger
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

Review 4.  Membrane recycling by coated vesicles.

Authors:  B M Pearse; M S Bretscher
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

5.  In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis.

Authors:  L Steinman; J T Rosenbaum; S Sriram; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

6.  Reversal of lethal digoxin toxicity in guinea pigs using monoclonal antibodies and Fab fragments.

Authors:  P Lechat; M Mudgett-Hunter; M N Margolies; E Haber; T W Smith
Journal:  J Pharmacol Exp Ther       Date:  1984-04       Impact factor: 4.030

7.  Specific immunosuppression by immunotoxins containing daunomycin.

Authors:  E Diener; U E Diner; A Sinha; S Xie; R Vergidis
Journal:  Science       Date:  1986-01-10       Impact factor: 47.728

8.  Treatment of 63 severely digitalis-toxic patients with digoxin-specific antibody fragments.

Authors:  T L Wenger; V P Butler; E Haber; T W Smith
Journal:  J Am Coll Cardiol       Date:  1985-05       Impact factor: 24.094

Review 9.  Strategies for treating autoimmune disease with monoclonal antibodies.

Authors:  D Wofsy
Journal:  West J Med       Date:  1985-12

10.  Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies.

Authors:  N E Adelman; D L Watling; H O McDevitt
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

View more
  13 in total

Review 1.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 2.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

Review 3.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis.

Authors:  Roarke A Kamber; Yoko Nishiga; Bhek Morton; Allison M Banuelos; Amira A Barkal; Felipe Vences-Catalán; Mingxin Gu; Daniel Fernandez; Jose A Seoane; David Yao; Katherine Liu; Sijie Lin; Kaitlyn Spees; Christina Curtis; Livnat Jerby-Arnon; Irving L Weissman; Julien Sage; Michael C Bassik
Journal:  Nature       Date:  2021-09-08       Impact factor: 69.504

5.  Pharmacokinetics of a mouse/human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients.

Authors:  J M Trang; A F LoBuglio; R H Wheeler; E B Harvey; L Sun; J Ghrayeb; M B Khazaeli
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

6.  Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.

Authors:  A Mori; S J Kennel; M van Borssum Waalkes; G L Scherphof; L Huang
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 7.  Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential.

Authors:  Larissa M Alvarenga; Muhammad Zahid; Anne di Tommaso; Matthieu O Juste; Nicolas Aubrey; Philippe Billiald; Julien Muzard
Journal:  Toxins (Basel)       Date:  2014-08-21       Impact factor: 4.546

8.  A Bioluminescence Resonance Energy Transfer-Based Approach for Determining Antibody-Receptor Occupancy In Vivo.

Authors:  Yu Tang; Kshitij Parag-Sharma; Antonio L Amelio; Yanguang Cao
Journal:  iScience       Date:  2019-05-08

9.  Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling

Authors:  Zahra Payandeh; Masoumeh Rajabibazl; Yousef Mortazavi; Azam Rahimpour; Amir Hossein Taromchi
Journal:  Iran Biomed J       Date:  2017-10-10

Review 10.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.